Clinical Trials Directory

Trials / Unknown

UnknownNCT01492270

Imaging for Significant Prostate Cancer Risk Evaluation

PICTURE - Prostate Imaging (Multi-parametric MRI and Prostate HistoScanning™) Compared to Transperineal Ultrasound Guided Biopsy for Significant Prostate Cancer Risk Evaluation.

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
126 (estimated)
Sponsor
University College London Hospitals · Academic / Other
Sex
Male
Age
20 Years
Healthy volunteers
Not accepted

Summary

The incidence of prostate cancer is rising however the number of deaths from prostate cancer is stable. Meaning the investigators are diagnosing many men with prostate cancer that will not impact on their life. The rise in incidence is mainly due to increased use of the blood test Prostate Specific Antigen (PSA), as a screening test. Currently men suspected of having prostate cancer, identified by a raised PSA undergo trans-rectal ultrasound guided prostate biopsy (TRUS biopsy). Many men have this test unnecessarily, only 1/3 being diagnosed with prostate cancer. TRUS biopsy is problematic as it is random and performed blind-the operator does not know where the cancer is. Thus many low-risk cancers that do not need treating are diagnosed and many high risk cancers are missed or incorrectly classified. So, men with a negative biopsy or those with low risk disease are usually advised to undergo another TRUS biopsy. An imaging test is needed that could help men and their doctors decide whether the biopsy is a true reflection of what is inside his prostate. The investigators will test the role of two imaging tests. The first, multi-parametric magnetic resonance imaging (mp-MRI) uses magnetic signals from the body to form images. The second, Prostate HistoScanning™ (PHS) uses sound-waves. The investigators will compare the results of these tests with a detailed biopsy map-transperineal template prostate mapping biopsy (which is currently the best way to find out what is in the prostate but requires multiple biopsies to be taken under general anaesthetic. Eligible men will have undergone one or more TRUS biopsies and who have been advised to have further tests on as part of standard of care. They will be recruited from UCLH referral letters and clinics. The investigators aim is to see if either of these tests can confidently rule out the presence of clinically important disease.

Conditions

Interventions

TypeNameDescription
PROCEDUREProstate HistoScanningAdvanced Ultrasound assessment of the prostate
PROCEDUREMulti-parametric MRIMulti-sequence Magnetic resonance imaging of the prostate
PROCEDURETransperineal prostate mapping biopsyNeedle biopsy of the perineum via the transperineal route at 5mm intervals guided by the use of ultrasound.
PROCEDUREImage guided biopsiesBiopsies targeted to lesions seen at a) Prostate HistoScanning and b) mp-MRI. In men with an MRI lesion further MRI/US registration biopsies will be obtained

Timeline

Start date
2011-12-01
Primary completion
2013-07-01
Completion
2013-07-01
First posted
2011-12-14
Last updated
2011-12-30

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT01492270. Inclusion in this directory is not an endorsement.